Washington University School of Medicine
The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal inflammation persist?
The purpose of this study is to combine multi-tracer PET and high-resolution CSF analysis to understand the inflammatory landscape of MS and to identify components of inflammation which do not resolve with high-efficacy DMT and are hypothesized to drive disability accumulation via smoldering inflammation. Identification of components of the pathologic cascade which do not respond to extant therapies will motivate future, complementary therapies targeted at yet untreated MS pathology. Current MS disease modifying therapies (DMT) focus on reducing the inflammatory or auto-immune component of th…
Inclusion Criteria: * Male or female, any race * Age ≥ 18 years * Capable of providing written informed consent for volunteering to undergo research procedures * Diagnosis of MS as established by the referring physician and confirmed by the Sponsor-Investigator. Only patients with active disease, defined as at least 1 enhancing lesion present in the preceding 6 months, will be enrolled * Treatment naïve except for relapse-related treatments such as corticosteroids or plasmapheresis, * Planned initiation, at the discretion of the referring physician, of a high efficacy DMT. High efficacy DMT w…
Radiotracer used in PET/CT scans of the head and neck Dose range: 12-17 mCi
Radiotracer used in PET/CT scans of the head and neck Dose range:15-20 mCi
MS treatment taken indepenently after initial testing
used in PET/CT scans of the head and neck Dose: 5-7 mCi
Arctuva estimate
Verify or correct the compensation shown for this listing.